With Additional Active Ingredient Patents (Class 514/171)
  • Patent number: 11364198
    Abstract: Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: June 21, 2022
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Arturo Angel, Chandelle Hermes
  • Patent number: 11344531
    Abstract: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 31, 2022
    Assignees: Servicio Andaluz de Salud, Universidad de Granada
    Inventors: Darío Acuña Castroviejo, Germaine Escames Rosa, Pablo Bueno Laraño, Alfonso Mansilla Roselló, José Antonio Ferrón Orihuela, José Jorge Hernández Magdalena, Miguel Ángel Calleja Hernández, Desirée González Callejas, Ana Comino Pardo, Carmen Olmedo Martín, Carmen Venegas Maldonado
  • Patent number: 11337987
    Abstract: The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3?-OH-5?-pregnan-20-one, or 3?-OH-5?-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: May 24, 2022
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Kilyoung Kim, Kongnara Papangkorn, Benjamin J. Bruno, Kiran Kumar Vangara
  • Patent number: 11332494
    Abstract: An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: May 17, 2022
    Assignee: Fernando Thome Kreutz
    Inventor: Fernando Thome Kreutz
  • Patent number: 11324694
    Abstract: A method of making a pharmaceutical composition for delivery to the lower respiratory tract via nebulization within a sterile diluent includes mixing dry powder ingredients including a beta agonist or anticholinergic and one or more additional ingredients to formulate a dry powder mixture for mixing with the sterile diluent.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: May 10, 2022
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 11324772
    Abstract: The present invention relates to a periodontal gel composition, more particularly to a liquid composition having a low viscosity at ambient temperature, which upon warming to body temperature solidifies into a viscous gel and then releases a therapeutic agent, e.g., an antibacterial agent, in a sustained release manner; and to a method of use.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 10, 2022
    Assignee: PRUDENTIX LTD.
    Inventors: Keren Mevorat Kaplan, Dadi Segal, Danny Rosenbaum, Igal Liapis, Igor Makarovsky, Meir Stern
  • Patent number: 11304960
    Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: April 19, 2022
    Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
  • Patent number: 11299497
    Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 12, 2022
    Assignee: UNION therapeutics A/S
    Inventors: Jens Larsen, Simon Feldbaek Nielsen, Peter Andersen
  • Patent number: 11292799
    Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 5, 2022
    Assignee: UNION THERAPEUTICS A/S
    Inventors: Mark Andrews, Daniel Rodriguez Greve, Jens Larsen
  • Patent number: 11268952
    Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: March 8, 2022
    Assignee: Firmenich Incorporated
    Inventors: Catherine Tachdjian, Andrew P. Patron, Sara L. Adamski-Werner, Farid Bakir, Qing Chen, Vincent Darmohusodo, Stephen Terrence Hobson, Xiaodong Li, Ming Qi, Daniel H. Rogers, Marketa Rinnova, Guy Servant, Xiao-Qing Tang, Mark Zoller, David Wallace, Amy Xing, Klaus Gubernator
  • Patent number: 11266663
    Abstract: Described herein are neurosteroids and analogues thereof and derivatives thereof, including, but not limited to, allopregnanolone, allopregnanolone analogues, and derivatives thereof that can be used for treatment of a neuropsychiatric disorder and/or symptom thereof. Also described herein are pharmaceutical formulations containing an effective amount of a neurosteroids and analogues thereof and derivatives thereof, where the effective amount can be effective for treating a neuropsychiatric disorder and/or symptom thereof. Also described herein are methods of treating a neuropsychiatric disorder and/or a symptom thereof in a subject in need thereof.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 8, 2022
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Graziano Pinna, Andrea Locci
  • Patent number: 11260062
    Abstract: Provided is a composition for treating or ameliorating lung cancer including a glucocorticoid-based compound, a glucocorticoid-based compound and an mTOR inhibitor, or a glucocorticoid-based compound and an AMPK inhibitor as an active ingredient. The glucocorticoid-based compounds inhibit the growth of cancer cells by suppressing NRF2 in KEAP1 mutant lung cancer or KEAP1 and LKB1 mutant lung cancer, and exhibit a more potent anticancer effect when used in combination with the mTOR inhibitor, and thus the compounds can be effectively used as anticancer agents for mutant lung cancer. Further, the glucocorticoid-based compounds exhibit a strong anticancer synergistic effect in a low nutritional state when treated in combination with an AMPK inhibitor in KEAP1 and LKB1 normal lung cancer, and thus the compounds can also be used as an anticancer agent for KEAP1 normal lung cancer.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 1, 2022
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Sang-Min Jeon
  • Patent number: 11241426
    Abstract: Provided is an aqueous composition for ophthalmic or nasal administration comprising levocetirizine or its salt. In one embodiment, the composition comprises levocetirizine or its salt at a levocetirizine concentration of 0.05-0.5% (w/v). The composition may further comprise a surface active agent and/or an organic acid salt.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 8, 2022
    Assignee: Nitto Medic Co., Ltd.
    Inventor: Mineo Onuki
  • Patent number: 11229655
    Abstract: The invention provides a fulvestrant composition comprising a pharmaceutically acceptable vehicle and not more than 2% total impurities and which, optionally, is free of a non-aqueous ester solvent. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: January 25, 2022
    Assignee: Fresenius Kabi USA, LLC
    Inventor: Jabar A. Faraj
  • Patent number: 11224575
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: January 18, 2022
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck
  • Patent number: 11197822
    Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: December 14, 2021
    Assignees: The Regents of the University of California, Meritage Pharma, Inc.
    Inventors: Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
  • Patent number: 11180488
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C3-8 cycl
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 23, 2021
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Hao Zhang, Yan Shi, Jun Li
  • Patent number: 11166978
    Abstract: The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: November 9, 2021
    Assignee: Seanergy Dermatology Ltd.
    Inventor: Doron Friedman
  • Patent number: 11154527
    Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 26, 2021
    Assignee: The Children's Mercy Hospital
    Inventors: Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder
  • Patent number: 11154528
    Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: October 26, 2021
    Assignee: Ventis Pharma
    Inventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
  • Patent number: 11124537
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 21, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Haiying Zhou, Minna Delarae Balbas, Valeria R. Fantin
  • Patent number: 11123323
    Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 21, 2021
    Assignee: MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT MBH
    Inventor: Harald Greve
  • Patent number: 11103510
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: August 31, 2021
    Assignee: Incyte Corporation
    Inventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
  • Patent number: 11091437
    Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 17, 2021
    Assignee: Purdue Research Foundation
    Inventors: Mohamed Seleem, Mingji Dai, Dexter Cameron Davis, Haroon Taj Mohammad
  • Patent number: 11083737
    Abstract: The disclosure provides a deflazacort therapy comprising, administering to a subject suffering from Duchenne muscular dystrophy (DMD) a fixed dose of deflazacort. Also provided is a deflazacort therapy comprising, increasing the deflazacort dosage when the subject loses ambulation; or, increasing the dosage of deflazacort administered during concomitant administration of a CYP3A4 inducer; or, decreasing the dosage of deflazacort administered during concomitant administration of a CYP3A inhibitor.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: August 10, 2021
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Stephen P. Wanaski, Virginia D. Schmith, Linda L. Grasfeder, Scott Joseph Brantley
  • Patent number: 11061027
    Abstract: This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 13, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Sean J. Pittock, Thomas J. Kryzer, Avi Gadoth, Andrew McKeon, Vanda A. Lennon, James P. Fryer
  • Patent number: 11052084
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: July 6, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert Davis
  • Patent number: 11026920
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: June 8, 2021
    Assignee: VYNE THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Patent number: 11014880
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 25, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Patent number: 10968216
    Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
  • Patent number: 10966930
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 6, 2021
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck
  • Patent number: 10925863
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: February 23, 2021
    Assignee: MERCATOR MEDYSTEMS, INC.
    Inventor: Kirk Patrick Seward
  • Patent number: 10905668
    Abstract: The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 2, 2021
    Assignee: BIOGEM S.C. A R.L.
    Inventors: Claudio Pisano, Sabrina Dallavalle, Raffaella Cincinelli, Lucio Merlini
  • Patent number: 10898495
    Abstract: Described herein are methods of promoting remyelination in a subject suffering from demyelination diseases by administering to the subject a combination of steroid hormones and Hedgehog signaling pathway modulators. Also described are methods of administering the combination of drugs, wherein the combination of drugs are in compositions adapted for nasal administration.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 26, 2021
    Assignee: M ET P PHARMA AG
    Inventors: Claudia Mattern, Elisabeth Traiffort, Michael Schumacher
  • Patent number: 10874638
    Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: December 29, 2020
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventor: Lin Zhi
  • Patent number: 10849911
    Abstract: The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: December 1, 2020
    Assignee: Galmed Research and Development Ltd.
    Inventors: Allen Baharaff, Idit Eshkar-Oren
  • Patent number: 10835502
    Abstract: This disclosure relates to a method of reducing a fat deposit comprising injecting an alcohol-containing pharmaceutical composition into the fat deposit. The method may be effective in improving the appearance of or reducing the weight or volume of the fat deposit.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: November 17, 2020
    Assignee: Polithera, Inc.
    Inventors: Adam M. Rotunda, Vince Afsahi
  • Patent number: 10835454
    Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 17, 2020
    Assignees: Corium, Inc., A.V. Topchiey Institute of Petrochemical Synthesis, Russian Academy of Sciences
    Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bayramov
  • Patent number: 10837971
    Abstract: Methods are provided for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17?-estradiol (E2a), 17?-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17?-dihydroequilin (EQa), 17?-dihydroequilin (EQb), Equilenin (EN), 17?-dihydroequilenin (ENa), 17?-dihydroequilenin (ENb), and ?8,9-dehydroestrone (dE1)) in a sample by mass spectrometry. The methods generally involve ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: November 17, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Mildred Goldman, Nigel Clarke
  • Patent number: 10813858
    Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 27, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Kunal Virendra Gujraty, Shikhar Gupta, Yan Yan, Naohisa Yoshimi
  • Patent number: 10780097
    Abstract: This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia. Patients at such high risk may be identified prior to their developing hypokalemia. Such a patient may be an adult patient with endogenous Cushing's Syndrome having type 2 diabetes mellitus or glucose intolerance to control hyperglycemia secondary to hypercortisolism. Patients may be identified by an above-threshold level of ACTH or cortisol in a patient sample taken post-GRM administration or pre-GRM administration, respectively. Upon identifying such a patient prior to the development of low potassium, the present methods provide for prophylactically treating the patient by administration of one or more hypokalemia treatments concurrently with an increased dose of GRM or with an initial dose of GRM to prevent hypokalemia.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 22, 2020
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Andreas Moraitis
  • Patent number: 10765684
    Abstract: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 8, 2020
    Assignee: Havah Therapeutics Pty Ltd.
    Inventor: Stephen Nigel Birrell
  • Patent number: 10765630
    Abstract: The present invention is a method of treating enteropathic arthritis in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), and/or a salt thereof; and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: September 8, 2020
    Assignee: SEN-JAM PHARMACEUTICAL LLC
    Inventors: Jacqueline Iversen, Thomas A. Dahl
  • Patent number: 10758554
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 1, 2020
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
  • Patent number: 10758544
    Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: September 1, 2020
    Assignee: CARDIX Therapeutics, LLC
    Inventors: Jin Jean Wang, Gerald J. Yakatan, Ting N. Lin, Jing H. Gao
  • Patent number: 10751347
    Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating optic neuropathy conditions.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 25, 2020
    Assignee: REGENERA PHARMA LTD.
    Inventors: Zadik Hazan, Andre C. B. Lucassen, Konstantin Adamsky
  • Patent number: 10751317
    Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: August 25, 2020
    Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: Catherine Ludlow, Aimee M. Dudley, Zhihao Tan
  • Patent number: 10751297
    Abstract: Provided herein are compositions and related methods for the treatment of herpes simplex virus (HSV) induced blisters and resulting ulcerative lesions. The composition includes at least one antiviral agent that is a long-chain aliphatic compound, and at least one topical corticosteroid.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: August 25, 2020
    Inventor: Kevin Mrohs
  • Patent number: 10716797
    Abstract: The present invention provides bacterial ATP synthase inhibitors such as a compound of formula (I): There are provided compositions and kits using such compounds and inhibitors.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: July 21, 2020
    Assignee: SOCPRA SCIENCES ET GÉNIE S.E.C.
    Inventors: Éric Marsault, François Malouin, Félix Chagnon, Isabelle Guay, Simon Boulanger
  • Patent number: 10702499
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 7, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick